PuSH - Publication Server of Helmholtz Zentrum München: Targeting pyruvate carboxylase reduces gluconeogenesis and adiposity and improves insulin resistance.

Information

Clues to quality of journals

Open Access Policy of Helmholtz Association 2016

CC Licencences

Publication Metrics

Navigation

Home

Deutsch

EVA: Electronic Publishing

New EVA Application

Research

Advanced Search

Browse by ...

... HMGU-Authors/Consortia

... Organizational Structure

... Journal

... Publication Type

... Research Data

... Arbeitsgruppen

... Publication Year

Publication overview

Statistics

Statistics (last 5 years)

OA Publications

Publish

Submit Publication

Import publication from...

...EVA

Report missing publication

Highlights

Support & Contact

Contact persons

Help

Data protection

Helmholtz Open Science

JANE Journal Estimator

SHERPA/RoMEO

DOAJ

Export:

Text

Endnote (RIS) BIB

BibTeX

Kumashiro, N.* ; Beddow, S.A.* ; Vatner, D.F.* ; Majumdar, S.K.* ; Cantley, J.L.* ; Guebre-Egziabher, F.* ; Fat, I.* ; Guigni, B.* ; Jurczak, M.J.* ; Birkenfeld, A.L.* ; Kahn, M.* ; Perler, B.K.* ; Puchowicz, M.A.* ; Manchem, V.P.* ; Bhanot, S.* ; Still, C.D.* ; Gerhard, G.S.* ; Petersen, K.F.* ; Cline, G.W.* ; Shulman, G.I.* ; Samuel, V.T.*

Targeting pyruvate carboxylase reduces gluconeogenesis and adiposity and improves insulin resistance.

Diabetes 62, 2183-2194 (2013)

DOI

PMC

Open Access Green as soon as Postprint is submitted to ZB.

Abstract
Metrics
Extra information

We measured the mRNA and protein expression of the key gluconeogenic enzymes in human liver biopsy specimens and found that only hepatic pyruvate carboxylase protein levels related strongly with glycemia. We assessed the role of pyruvate carboxylase in regulating glucose and lipid metabolism in rats through a loss-of-function approach using a specific antisense oligonucleotide (ASO) to decrease expression predominantly in liver and adipose tissue. Pyruvate carboxylase ASO reduced plasma glucose concentrations and the rate of endogenous glucose production in vivo. Interestingly, pyruvate carboxylase ASO also reduced adiposity, plasma lipid concentrations, and hepatic steatosis in high fat-fed rats and improved hepatic insulin sensitivity. Pyruvate carboxylase ASO had similar effects in Zucker Diabetic Fatty rats. Pyruvate carboxylase ASO did not alter de novo fatty acid synthesis, lipolysis, or hepatocyte fatty acid oxidation. In contrast, the lipid phenotype was attributed to a decrease in hepatic and adipose glycerol synthesis, which is important for fatty acid esterification when dietary fat is in excess. Tissue-specific inhibition of pyruvate carboxylase is a potential therapeutic approach for nonalcoholic fatty liver disease, hepatic insulin resistance, and type 2 diabetes.

Impact Factor

Scopus SNIP

Scopus
Cited By

Altmetric

0.000

2.093